Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayden, M. R.
Right arrow Articles by Pate, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayden, M. R.
Right arrow Articles by Pate, B. D.
NEUROLOGY 1986;36:888
© 1986 American Academy of Neurology

Positron emission tomography in the early diagnosis of Huntington's disease

M. R. Hayden, W.R.W. Martin, A. J. Stoessl, C. Clark, S. Hollenberg, M. J. Adam, W. Ammann, R. Harrop, J. Rogers, T. Ruth, C. Sayre and B. D. Pate

Department of Medical Genetics and Internal Medicine (Drs. Hayden and Hollenberg), Division of Neurology (Drs. Martin and Stoessl), Department of Psychiatry (Dr. Clark), and the UBC/Triumf PET Group (Drs. Martin, Adam, Ammann, Harrop, Rogers, Ruth, Sayre, and Pate), University of British Columbia, Vancouver, BC, Canada.

We studied 10 patients with early Huntington's disease and 7 normal age-matched controls with positron emission tomography (PET) using fluorodeoxyglucose. Subjects had little or no caudate nucleus atrophy and had not received any medications. The results demonstrated that hypometabolism of glucose preceded tissue loss. Furthermore, patients with minimal neurologic or psychiatric symptoms and no obvious CT changes may be differentiated from normal persons with high accuracy by PET. PET is helpful in the early diagnosis of Huntington's disease irrespective of the mode of presentation. PET may also be useful for preclinical detection and may supplement information from DNA studies.

Address correspondence and reprint requests to Dr. Hayden, Department of Medical Genetics, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.

Supported by grants from the MRC of Canada, the Huntington Society of Canada, the Dystonia Medical Research Foundation, and the British Columbia Health Care Research Foundation.

Accepted for publication October 30, 1985.




This article has been cited by other articles:


Home page
 BrainHome page
M. A. Pouladi, R. K. Graham, J. M. Karasinska, Y. Xie, R. D. Santos, A. Petersen, and M. R. Hayden
Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin
Brain, April 1, 2009; 132(4): 919 - 932.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Feigin, K. L. Leenders, J. R. Moeller, J. Missimer, G. Kuenig, P. Spetsieris, A. Antonini, and D. Eidelberg
Metabolic Network Abnormalities in Early Huntington's Disease: An [18F]FDG PET Study
J. Nucl. Med., November 1, 2001; 42(11): 1591 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. S. Paulsen, H. Zhao, J. C. Stout, R. R. Brinkman, M. Guttman, C. A. Ross, P. Como, C. Manning, M. R. Hayden, and I. Shoulson
Clinical markers of early disease in persons near onset of Huntington's disease
Neurology, August 28, 2001; 57(4): 658 - 662.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
L H Pinborg, C Videbak, S G Hasselbalch, S A Sorensen, A Wagner, O B Paulson, and G M Knudsen
Benzodiazepine receptor quantification in Huntington's disease with [123I]iomazenil and SPECT
J. Neurol. Neurosurg. Psychiatry, May 1, 2001; 70(5): 657 - 661.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
G. J. Harris, A. M. Codori, R. F. Lewis, E. Schmidt, A. Bedi, and J. Brandt
Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease
Brain, September 1, 1999; 122(9): 1667 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Kremer, C. M. Clark, E. W. Almqvist, L. A. Raymond, P. Graf, C. Jacova, M. Mezei, M. A. Hardy, B. Snow, W. Martin, et al.
Influence of lamotrigine on progression of early Huntington disease: A randomized clinical trial
Neurology, September 1, 1999; 53(5): 1000 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
G. J. Harris, E. H. Aylward, C. E. Peyser, G. D. Pearlson, J. Brandt, J. V. Roberts-Twillie, P. E. Barta, and S. E. Folstein
Single Photon Emission Computed Tomographic Blood Flow and Magnetic Resonance Volume Imaging of Basal Ganglia in Huntington's Disease
Arch Neurol, April 1, 1996; 53(4): 316 - 324.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
O. Godefroy, M. Rousseaux, D. Leys, A. Destee, P. Scheltens, and J. P. Pruvo
Frontal Lobe Dysfunction in Unilateral Lenticulostriate Infarcts: Prominent Role of Cortical Lesions
Arch Neurol, December 1, 1992; 49(12): 1285 - 1289.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
S. T. Grafton, J. C. Mazziotta, J. J. Pahl, P. St. George-Hyslop, J. L. Haines, J. Gusella, J. M. Hoffman, L. R. Baxter, and M. E. Phelps
Serial Changes of Cerebral Glucose Metabolism and Caudate Size in Persons at Risk for Huntington's Disease
Arch Neurol, November 1, 1992; 49(11): 1161 - 1167.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
G. W. Jason, E. M. Pajurkova, O. Suchowersky, J. Hewitt, C. Hilbert, J. Reed, and M. R. Hayden
Presymptomatic Neuropsychological Impairment in Huntington's Disease
Arch Neurol, July 1, 1988; 45(7): 769 - 773.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.